Newfeed

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS)1,2iDFS benefit remains consistent across key patient

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: